Kymera Therapeutics (KYMR) Stock Forecast & Price Target

Compare

367 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KYMR Analyst Ratings

Strong Buy

18 Buy

0 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Kymera

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KYMR Stock 12 Month Forecast

Average Price Target

$63.50

▲(18.16% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Kymera Therapeutics in the last 3 months. The average price target is $63.50 with a high forecast of $88.00 and a low forecast of $53.00. The average price target represents a 18.16% change from the last price of $53.74.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","89":"$89","40.25":"$40.3","56.5":"$56.5","72.75":"$72.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$88.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$63.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$53.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,40.25,56.5,72.75,89],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.69,44.32923076923077,47.96846153846154,51.607692307692304,55.246923076923075,58.886153846153846,62.52538461538461,66.16461538461539,69.80384615384615,73.44307692307692,77.0823076923077,80.72153846153846,84.36076923076922,{"y":88,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.69,42.44461538461538,44.199230769230766,45.95384615384615,47.708461538461535,49.46307692307692,51.2176923076923,52.972307692307695,54.72692307692307,56.48153846153846,58.23615384615384,59.99076923076923,61.745384615384616,{"y":63.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.69,41.636923076923075,42.58384615384615,43.53076923076923,44.47769230769231,45.424615384615386,46.371538461538464,47.318461538461534,48.26538461538461,49.21230769230769,50.15923076923077,51.106153846153845,52.05307692307692,{"y":53,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":48.36,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.57,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.23,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.35,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$88.00

Average Price Target$63.50

Lowest Price Target$53.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Fein

H.C. Wainwright

$60→$70

Buy

30.26%

Upside

Reiterated

09/18/25

Kymera Therapeutics price target raised to $70 from $60 at H.C. WainwrightKymera Therapeutics price target raised to $70 from $60 at H.C. Wainwright

Jeff Jones

Oppenheimer

$53

Buy

-1.38%

Downside

Reiterated

09/18/25

Oppenheimer Sticks to Their Buy Rating for Kymera Therapeutics (KYMR)

Judah Frommer

Morgan Stanley

$70

Buy

30.26%

Upside

Reiterated

09/17/25

Kymera Therapeutics: Promising Developments and Buy Rating Amidst Significant Clinical Advancements

Etzer Darout

Barclays

$60

Buy

11.65%

Upside

Initiated

09/16/25

Kymera Therapeutics initiated with an Overweight at BarclaysKymera Therapeutics initiated with an Overweight at Barclays

Brian Abrahams

RBC Capital

$70

Buy

30.26%

Upside

Initiated

09/16/25

Kymera Therapeutics initiated with an Outperform at RBC CapitalKymera Therapeutics initiated with an Outperform at RBC Capital

Jeet Mukherjee

BTIG

$59

Buy

9.79%

Upside

Reiterated

09/15/25

BTIG Remains a Buy on Kymera Therapeutics (KYMR)

Tazeen Ahmad

Bank of America Securities

$54

Buy

0.48%

Upside

Reiterated

09/15/25

Bank of America Securities Remains a Buy on Kymera Therapeutics (KYMR)We maintain our Buy with $54 PO.

Derek Archila

Wells Fargo

$53

Buy

-1.38%

Downside

Reiterated

09/11/25

Analysts Are Bullish on Top Healthcare Stocks: Dermata Therapeutics (DRMA), Kymera Therapeutics (KYMR)

Andy Chen

Wolfe Research

$53→$88

Buy

63.75%

Upside

Reiterated

09/11/25

Kymera Therapeutics (KYMR) Gets a Buy from Wolfe ResearchWolfe Research analyst Andy Chen raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $88.00 (from $53.00) while maintaining a Outperform rating.

Brian Cheng

J.P. Morgan

$64

Buy

19.09%

Upside

Reiterated

08/21/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Faisal Khurshid

Leerink Partners

$60→$62

Buy

15.37%

Upside

Reiterated

08/12/25

Kymera Therapeutics: Promising Clinical Developments and Strategic Positioning in STAT6 Landscape Justify Buy Rating

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

08/12/25

Truist Financial Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

Michael Schmidt

Guggenheim

$60

Buy

11.65%

Upside

Reiterated

08/11/25

Guggenheim Keeps Their Buy Rating on Kymera Therapeutics (KYMR)Maintain our Buy rating and $60/shr PT.

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

08/11/25

Kymera Therapeutics: Strong Financials and Promising Clinical Results Justify Buy RatingWe expect this data to ultimately translate into robust clinical activity (EASI scores, downstream transcriptomics, etc.) in patients with AD. Additional details can be found in our prior note.

Geoff Meacham

Citi

$60

Buy

11.65%

Upside

Reiterated

08/11/25

Kymera Therapeutics: Promising Developments and Strong Financial Position Support Buy Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Fein

H.C. Wainwright

$60→$70

Buy

30.26%

Upside

Reiterated

09/18/25

Kymera Therapeutics price target raised to $70 from $60 at H.C. WainwrightKymera Therapeutics price target raised to $70 from $60 at H.C. Wainwright

Jeff Jones

Oppenheimer

$53

Buy

-1.38%

Downside

Reiterated

09/18/25

Oppenheimer Sticks to Their Buy Rating for Kymera Therapeutics (KYMR)

Judah Frommer

Morgan Stanley

$70

Buy

30.26%

Upside

Reiterated

09/17/25

Kymera Therapeutics: Promising Developments and Buy Rating Amidst Significant Clinical Advancements

Etzer Darout

Barclays

$60

Buy

11.65%

Upside

Initiated

09/16/25

Kymera Therapeutics initiated with an Overweight at BarclaysKymera Therapeutics initiated with an Overweight at Barclays

Brian Abrahams

RBC Capital

$70

Buy

30.26%

Upside

Initiated

09/16/25

Kymera Therapeutics initiated with an Outperform at RBC CapitalKymera Therapeutics initiated with an Outperform at RBC Capital

Jeet Mukherjee

BTIG

$59

Buy

9.79%

Upside

Reiterated

09/15/25

BTIG Remains a Buy on Kymera Therapeutics (KYMR)

Tazeen Ahmad

Bank of America Securities

$54

Buy

0.48%

Upside

Reiterated

09/15/25

Bank of America Securities Remains a Buy on Kymera Therapeutics (KYMR)We maintain our Buy with $54 PO.

Derek Archila

Wells Fargo

$53

Buy

-1.38%

Downside

Reiterated

09/11/25

Analysts Are Bullish on Top Healthcare Stocks: Dermata Therapeutics (DRMA), Kymera Therapeutics (KYMR)

Andy Chen

Wolfe Research

$53→$88

Buy

63.75%

Upside

Reiterated

09/11/25

Brian Cheng

J.P. Morgan

$64

Buy

19.09%

Upside

Reiterated

08/21/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Faisal Khurshid

Leerink Partners

$60→$62

Buy

15.37%

Upside

Reiterated

08/12/25

Kymera Therapeutics: Promising Clinical Developments and Strategic Positioning in STAT6 Landscape Justify Buy Rating

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

08/12/25

Truist Financial Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

Michael Schmidt

Guggenheim

$60

Buy

11.65%

Upside

Reiterated

08/11/25

Guggenheim Keeps Their Buy Rating on Kymera Therapeutics (KYMR)Maintain our Buy rating and $60/shr PT.

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

08/11/25

Geoff Meacham

Citi

$60

Buy

11.65%

Upside

Reiterated

08/11/25

Kymera Therapeutics: Promising Developments and Strong Financial Position Support Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kymera Therapeutics

1 Month

xxx

Success Rate

9/13 ratings generated profit

Average Return

+11.58%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 69.23% of your transactions generating a profit, with an average return of +11.58% per trade.

3 Months

xxx

Success Rate

9/14 ratings generated profit

Average Return

+9.40%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +9.40% per trade.

1 Year

Faisal KhurshidLeerink Partners

Success Rate

9/10 ratings generated profit

Average Return

+31.72%

reiterated a buy rating 2 months ago

Copying Faisal Khurshid's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +31.72% per trade.

2 Years

xxx

Success Rate

13/13 ratings generated profit

Average Return

+55.65%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +55.65% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KYMR Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KYMR has received 24 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. KYMR average Analyst price target in the past 3 months is 63.50.

Each month's total comprises the sum of three months' worth of ratings.

KYMR Financial Forecast

KYMR Earnings Forecast

Next quarter’s earnings estimate for KYMR is -$0.76 with a range of -$1.15 to $0.18. The previous quarter’s EPS was -$0.95. KYMR beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.82% of the time in the same period. In the last calendar year KYMR has Outperformed its overall industry.

KYMR Sales Forecast

Next quarter’s sales forecast for KYMR is $23.80M with a range of $5.00M to $109.00M. The previous quarter’s sales results were $11.48M. KYMR beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 54.41% of the time in the same period. In the last calendar year KYMR has Outperformed its overall industry.

KYMR Stock Forecast FAQ

What is KYMR’s average 12-month price target, according to analysts?

Based on analyst ratings, Kymera Therapeutics’s 12-month average price target is 63.50.

What is KYMR’s upside potential, based on the analysts’ average price target?

Kymera Therapeutics has 18.16% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KYMR a Buy, Sell or Hold?

Kymera Therapeutics has a consensus rating of Strong Buy which is based on 18 buy ratings, 0 hold ratings and 0 sell ratings.

What is Kymera Therapeutics’s price target?

The average price target for Kymera Therapeutics is 63.50. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $88.00 ,the lowest forecast is $53.00. The average price target represents 18.16% Increase from the current price of $53.74.

What do analysts say about Kymera Therapeutics?

Kymera Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of KYMR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Kymera Therapeutics (KYMR) Stock Forecast & Price Target

KYMR Analyst Ratings

KYMR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Kymera Therapeutics

KYMR Analyst Recommendation Trends

KYMR Financial Forecast

KYMR Earnings Forecast

KYMR Sales Forecast

KYMR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts